| Description | ZZL-7 is a fast-onset antidepressant agent. ZZL-7 disrupts the interaction between the neuronal nitric oxide synthase (nNOS) and serotonin transporter (SERT) in the dorsal raphe nucleus (DRN). ZZL-7 can easily cross the blood-brain barrier readily. ZZL-7 has research value in major depressive disorder (MDD). |
| In vitro | 在转染了nNOS和SERT的293T细胞中，ZZL-7（1.0 μM；2小时）显著降低了SERT-nNOS复合物的水平[1]。 |
| In vivo | ZZL-7（10 mg/kg；腹腔注射）能在治疗后2小时内逆转慢性不可预测轻度压力（CMS）引起的抑郁行为。相同时间内，ZZL-7通过口服给药（10、20和40 mg/kg；单次）依剂量产生类抗抑郁行为。此外，ZZL-7（10 mg/kg，腹腔注射）在SERT-Cre小鼠的体内电生理学研究中，显著增加了血清素神经元的放电频率。在野生型小鼠中，ZZL-7减少了不动时间[1]。 |
| molecular weight | 244.29 |
| Molecular formula | C11H20N2O4 |
| CAS | 99141-91-0 |
| Storage | |Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 12 mg/mL (49.12 mM) |
| References | 1. Nan Sun, et al. Design of fast-onset antidepressant by dissociating SERT from nNOS in the DRN. Science. 2022 Oct 28;378(6618):390-398. |